New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 21, 2014
09:38 EDTESRXExpress Scripts TRICARE contract removes key overhang, says Citigroup
Citigroup believes the Express Scripts retaining the Department of Defense's TRICARE Pharmacy Program contract removes a key overhang on the stock and validates the company's business model. Citi reiterates a Buy rating on Express Scripts with a $92 price target.
News For ESRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent ESRX news | >>
December 22, 2014
13:18 EDTESRXGilead sinks after AbbVie hep C regimen selected by Express Scripts
Subscribe for More Information
12:20 EDTESRXGilead pullback a buying opportunity, says Wells Fargo
Wells Fargo sees a limited financial impact to Gilead (GILD) from Express Scripts (ESRX) selecting AbbVie's (ABBV) Viekira as the exclusive treatment option for GT-1 hepatitis patients. Wells thinks Gilead's Harvoni should be the preferred treatment by clinicians and patients, and thinks other payers will consider the totality of data supporting Harvoni's advantages. It recommends buying shares of Gilead on today's sell-off.
12:18 EDTESRXOn The Fly: Midday Wrap
Subscribe for More Information
11:41 EDTESRXGilead still uniquely postioned in HCV space, says Piper Jaffray
Subscribe for More Information
10:56 EDTESRXGilead sell-off on HCV deal 'way overdone,' says UBS
UBS says today's sell-off in shares of Gilead (GILD) is "way overdone." It views Express Scripts' (ESRX) deal with AbbVie (ABBV) as an incremental negative given the reach of the pharmacy benefits manager's coverage, but thinks the $15B taken off of Gilead's market cap is excessive. The firm estimates Express Scripts' formulary change will impact 30K-40K hepatitis C cases in 2015 out of the 177K treated. UBS thinks Gilead can still retain the majority of non-Express Scripts HCV business. It has a Buy rating on the stock with a $125 price target. Shares of the drug maker are down $13.64 to $94.81 in morning trading.
10:42 EDTESRXExpress Scripts hepatitis C deal a positive, says Leerink
Subscribe for More Information
10:00 EDTESRXGilead volatility increases after Express Scripts picks AbbVie for hepatitis C
Subscribe for More Information
09:24 EDTESRXOn The Fly: Pre-market Movers
HIGHER: Caesars Entertainment (CZR), up 23.8% following agreement to merge with Caesars Acquisition (CACQ)... Synthetic Biologics (SYN), up 8.6% following positive topline results from SYN-004 Phase 1a trial... Advaxis (ADXS), up 6.1% after Adage Capital Partners reports 18.84% passive stake in Advaxis... TASER (TASR), up 4.25% following multiple orders of Smart Weapons and Conducted Electrical Weapons... BioCryst Pharmaceuticals (BCRX), up 3.4% after RAPIVAB receives FDA approval... Herbalife (HLF), up 1.4% following a New York Post report that the FDA asked the company to stop airing a video claiming FDA approval. LOWER: Ocwen Financial (OCN), down 10.5% following settlement agreement with New York Department of Financial Services. NOTABLE: Enanta Pharmaceuticals (ENTA), up 11.8% following FDA approval of AbbVie's Viekira Pak... AbbVie is (ABBV) is up 2.4% following FDA approval of Viekira Pak and that Express Scripts (ESRX) will expand access to Viekira Pak... Express Scripts is trading marginally higher... Gilead Sciences (GILD), down 11.3% after Express Scripts picks AbbVie for hepatitis C.
08:54 EDTESRXExpress Scripts says hoping more companies take AbbVie view on opening access
Express Scripts (ESRX) CEO George Paz says AbbVie's (ABBV) Hep C drug compliance was "really high" in trials and that the company was focused on opening up access to its drug with the deal it struck with Express Scripts. Paz believes drug prices are "unsustainable" at recent levels and he believes deals like the one his company struck with AbbVie can be extended to other therapeutic areas. Paz was speaking on CNBC.
07:07 EDTESRXExpress Scripts and AbbVie to expand access to Viekira Pak
Subscribe for More Information
06:39 EDTESRXHepatitis C deal a blow to biotech bull market, The Street's Feuerstein says
Subscribe for More Information
06:29 EDTESRXGilead drops 4% after Express Scripts picks AbbVie for hepatitis C
Shares of Gilead (GILD) are moving lower in pre-market trading after Express Scripts (ESRX) spokesman Brian Henry told CNBC's Meg Tirrell and other news outlets that the pharmacy benefits manger will exclusively offer AbbVie's (ABBV) recently approved hepatitis C regimen Viekira Pak at a "significant discount" starting Jan. 1. Express Scripts will no longer offer competing drugs from Gilead and Johnson & Johnson (JNJ). Shares of AbbVie are rising 6% to $71.50 in pre-market trading while Gilead is down 4% to $104.15. AbbVie discovered part of the Viekira Pak regimen via its ongoing collaboration with Enanta Pharmaceuticals (ENTA). Shares of Enanta are up 7% to $49.96 in pre-open trading.
05:44 EDTESRXExpress Scripts to offer AbbVie hepatitis C drug exclusively, CNBC reports
Express Scripts (ESRX) will offer AbbVie's (ABBV) just approved hepatitis C regimen Viekira Pak at a "significant discount" starting Jan. 1, while excluding competing drugs from Gilead (GILD) and Johnson & Johnson (JNJ), CNBC's Meg Tirrell reports, citing comments from the pharmacy benefits manager's spokesman Brian Henry. Reference Link
December 16, 2014
08:22 EDTESRXExpress Scripts CFO change a 'modest' concern, says Leerink
Subscribe for More Information
07:47 EDTESRXExpress Scripts new CFO experience reassuring, says Oppenheimer
Subscribe for More Information
December 15, 2014
16:40 EDTESRXExpress Scripts backs FY14 EPS view $4.86-$4.90, consensus $4.88
Subscribe for More Information
16:39 EDTESRXExpress Scripts increases share repurchase authorization by 65M shares
Subscribe for More Information
16:37 EDTESRXExpress Scripts CFO Cathy Smith leaving company
Subscribe for More Information
07:40 EDTESRXExpress Scripts price target raised to $96 from $82 at UBS
Subscribe for More Information
December 8, 2014
11:30 EDTESRXLeerink generics pharmaceutical analyst holds analyst/industry conference call
Subscribe for More Information
1 | 2 | all recent ESRX news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use